logo
  

Fresh Vine Wine Inks Merger LoI With Notes Live

Fresh Vine Wine Inc. (VINE), a beverages company, announced on Monday that it has entered into a non-binding letter of intent or LoI for its merger with Notes Live, Inc., a live entertainment and hospitality firm.

The companies expect that a definitive deal will be executed by January 31, with a closing in the second quarter of 2024.

The two parties anticipate that the owners of Notes Live would own a majority of the Fresh Vine on a post-transaction basis, which may be more than 90 percent.

Post transaction, Fresh Vine will continue to remain listed on the NYSE.

In connection with the LoI, Fresh Vine has agreed to make a $500,000 equity investment in Notes Lives.

Fresh Vines' equity investment may be refundable under certain circumstances if Notes Live elects not to proceed with the transaction.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings... Target Corp. shares were losing more than 8 percent in pre-market activity on the NYSE after the general merchandise retailer reported weak profit, sales and comparable sales in its first quarter. Earnings per share missed the Street estimates. Further, the company issued second-quarter outlook and maintained fiscal 2024 forecast. Shares of Marks and Spencer Group Plc or M&S were gaining more than 7 percent in the morning trading in London after the retail major reported Wednesday significantly higher profit and sales in its fiscal 2024. The company also announced a dividend, and said it is confident to make further progress in 2025 and beyond.

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT